Silence Therapeutics Future Growth
Future criteria checks 2/6
Silence Therapeutics's earnings are forecast to decline at 11.5% per annum while its annual revenue is expected to grow at 34.4% per year. EPS is expected to grow by 18.3% per annum. Return on equity is forecast to be -72.3% in 3 years.
Key information
-11.5%
Earnings growth rate
18.3%
EPS growth rate
| Biotechs earnings growth | 30.3% |
| Revenue growth rate | 34.4% |
| Future return on equity | -72.3% |
| Analyst coverage | Low |
| Last updated | 16 Aug 2024 |
Recent future growth updates
Recent updates
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 18
Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit
Jun 17Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation
May 21Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues
Feb 07Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%
Nov 27Silence Therapeutics wins FDA’s fast track status for blood cancer therapy
Sep 08Silence Therapeutics prices 5.95M ADSs at $9.50/share
Aug 12New finance chief for Silence Therapeutics
Jan 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 16 | -88 | -102 | N/A | 3 |
| 12/31/2025 | 29 | -75 | -87 | N/A | 5 |
| 12/31/2024 | 23 | -51 | -56 | N/A | 5 |
| 6/30/2024 | 18 | -40 | N/A | N/A | N/A |
| 3/31/2024 | 26 | -35 | -39 | -39 | N/A |
| 12/31/2023 | 25 | -43 | -39 | -39 | N/A |
| 9/30/2023 | 28 | -43 | -41 | -41 | N/A |
| 6/30/2023 | 29 | -41 | -46 | -45 | N/A |
| 3/31/2023 | 23 | -43 | -39 | -39 | N/A |
| 12/31/2022 | 18 | -40 | -46 | -45 | N/A |
| 9/30/2022 | 16 | -36 | -35 | -34 | N/A |
| 6/30/2022 | 16 | -39 | -31 | -30 | N/A |
| 3/31/2022 | 15 | -39 | 3 | 5 | N/A |
| 12/31/2021 | 12 | -39 | 5 | 7 | N/A |
| 9/30/2021 | 11 | -42 | 3 | 4 | N/A |
| 6/30/2021 | 10 | -42 | 2 | 2 | N/A |
| 3/31/2021 | 8 | -35 | -24 | -23 | N/A |
| 12/31/2020 | 5 | -33 | -11 | -11 | N/A |
| 9/30/2020 | 3 | -26 | 0 | 1 | N/A |
| 6/30/2020 | 1 | -22 | 12 | 13 | N/A |
| 3/31/2020 | 1 | -21 | 7 | 7 | N/A |
| 12/31/2019 | 0 | -20 | 2 | 2 | N/A |
| 9/30/2019 | 0 | -19 | -8 | -8 | N/A |
| 6/30/2019 | N/A | -18 | -18 | -18 | N/A |
| 3/31/2019 | N/A | -18 | -18 | -18 | N/A |
| 12/31/2018 | N/A | -18 | -17 | -17 | N/A |
| 9/30/2018 | N/A | -12 | -15 | -15 | N/A |
| 6/30/2018 | N/A | -5 | -14 | -14 | N/A |
| 3/31/2018 | 0 | -3 | N/A | -12 | N/A |
| 12/31/2017 | 0 | -2 | N/A | -10 | N/A |
| 9/30/2017 | 0 | -5 | N/A | -9 | N/A |
| 6/30/2017 | 1 | -9 | N/A | -9 | N/A |
| 3/31/2017 | 1 | -9 | N/A | -9 | N/A |
| 12/31/2016 | 1 | -8 | N/A | -10 | N/A |
| 9/30/2016 | 0 | -8 | N/A | -10 | N/A |
| 6/30/2016 | N/A | -7 | N/A | -9 | N/A |
| 3/31/2016 | N/A | -7 | N/A | -9 | N/A |
| 12/31/2015 | N/A | -7 | N/A | -8 | N/A |
| 9/30/2015 | 0 | -8 | N/A | -9 | N/A |
| 6/30/2015 | 0 | -10 | N/A | -9 | N/A |
| 3/31/2015 | 0 | -10 | N/A | -9 | N/A |
| 12/31/2014 | 0 | -11 | N/A | -9 | N/A |
| 9/30/2014 | 0 | -11 | N/A | -9 | N/A |
| 6/30/2014 | 0 | -11 | N/A | -9 | N/A |
| 3/31/2014 | 0 | -10 | N/A | -8 | N/A |
| 12/31/2013 | 0 | -9 | N/A | -7 | N/A |
| 9/30/2013 | 0 | -8 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SLN's revenue (34.4% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: SLN's revenue (34.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SLN is forecast to be unprofitable in 3 years.